Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02258464 · ClinicalTrials.gov registry record · Phase 2
Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
A Phase 2 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
NCT02258464 is a Phase 2 study that was terminated before completion, run by Bayer. The registered enrollment target is 99 participants.
The verdict
NCT02258464, a Phase 2 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
Study Summary
The objective of this study was to assess efficacy and safety of radium-223 dichloride in subjects with human epidermal growth factor receptor 2 negative (HER2 negative) hormone receptor positive breast cancer with bone metastases treated with hormonal treatment background therapy
Interventions
- DRUG Radium-223 dichloride (Xofigo, BAY88-8223)
- DRUG Placebo (saline)
- OTHER Background hormonal therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2015-03-02 |
| Est. Completion | 2019-08-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02258464
The ClinicalTrials.gov registry entry for NCT02258464 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Radium-223 dichloride (Xofigo, BAY88-8223) is the first listed.
NCT02258464 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02258464 about?
NCT02258464 is a clinical study titled "Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer". The objective of this study was to assess efficacy and safety of radium-223 dichloride in subjects with human epidermal growth factor receptor 2 negative (HER2 negative) hormone receptor positive breast cancer with bone metastases treated with hormonal treatment background therapy
What is the current status of trial NCT02258464?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2015-03-02. Estimated completion is 2019-08-13.
What interventions are being tested in trial NCT02258464?
The interventions under investigation include: Radium-223 dichloride (Xofigo, BAY88-8223) (DRUG), Placebo (saline) (DRUG), Background hormonal therapy (OTHER).
Who is sponsoring clinical trial NCT02258464?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.